Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumors
US-2015366955-A9 · Dec 24, 2015 · US
Compositions and methods comprising KLK3 or FOLH1 antigen
US11446369B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11446369-B2 |
| Application number | US-201916672362-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 1, 2019 |
| Priority date | May 10, 2007 |
| Publication date | Sep 20, 2022 |
| Grant date | Sep 20, 2022 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention provides KLK3 peptides, FOLH1 peptides, recombinant polypeptides comprising same, recombinant nucleotide molecules encoding same, recombinant Listeria strains comprising same, and immunogenic and therapeutic methods utilizing same.
First claim
Opening claim text (preview).
What is claimed: 1. A method of inhibiting prostate cancer metastasis in a subject, comprising: administering to the subject a composition comprising a recombinant Listeria strain encoding a recombinant fusion peptide consisting of a KLK3 peptide operatively linked to a non-KLK3 peptide, wherein the non-KLK3 peptide is a N-terminal non-hemolytic listeriolysin (LLO) peptide, the fusion peptide consisting of the sequence of SEQ ID NO: 54 or a sequence at least 99% homologous (throughout the length of the peptide), wherein the metastasis is inhibited. 2. The method of claim 1 , wherein the recombinant Listeria strain is an auxotrophic Listeria. 3. The method of claim 2 , wherein the auxotrophic Listeria strain is a dal/dat mutant comprising a deletion in the endogenous ActA gene. 4. The method of claim 2 , wherein the auxotrophic Listeria strain comprises an episomal expression vector encoding a metabolic enzyme that complements the auxotrophy of the auxotrophic Listeria strain. 5. The method of claim 4 , wherein the metabolic enzyme is an alanine racemase enzyme. 6. The method of claim 4 , wherein the metabolic enzyme is a D-amino acid transferase enzyme. 7. The method of claim 1 , wherein the recombinant Listeria is a recombinant Listeria monocytogenes strain. 8. The method of claim 1 , wherein the inhibiting prostate cancer metastasis comprises metastasis-free prostate cancer progression. 9. The method of claim 1 , wherein the inhibiting prostate cancer metastasis comprises a reduced rate of growth or reduced number of prostate cancer metastases. 10. A method of treating prostate cancer metastasis in a subject, comprising: administering to the subject a composition comprising a recombinant Listeria strain encoding a recombinant fusion peptide consisting of a KLK3 peptide operatively linked to a non-KLK3 peptide, wherein the non-KLK3 peptide is a N-terminal non-hemolytic listeriolysin (LLO) peptide, the fusion peptide consisting of the sequence of SEQ ID NO: 54 or a sequence at least 99% homologous (throughout the length of the peptide), wherein the subject has metastatic prostate cancer. 11. The method of claim 10 , wherein the recombinant Listeria strain is an auxotrophic Listeria. 12. The method of claim 10 , wherein the auxotrophic Listeria strain is a dal/dat mutant comprising a deletion in the endogenous ActA gene. 13. The method of claim 10 , wherein the auxotrophic Listeria strain comprises an episomal expression vector encoding a metabolic enzyme that complements the auxotrophy of the auxotrophic Listeria strain. 14. The method of claim 13 , wherein the metabolic enzyme is an alanine racemase enzyme. 15. The method of claim 13 , wherein the metabolic enzyme is a D-amino acid transferase enzyme. 16. The method of claim 10 , wherein the recombinant Listeria is a recombinant Listeria monocytogenes strain.
Assignees
Inventors
Classifications
from bacteria · CPC title
Glutamate carboxypeptidase II (3.4.17.21) · CPC title
DNA (RNA) vaccination · CPC title
Bacterial antigens · CPC title
Semenogelase (3.4.21.77), i.e. prostate specific antigen or PSA or kallikrein 3 · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11446369B2 cover?
- The present invention provides KLK3 peptides, FOLH1 peptides, recombinant polypeptides comprising same, recombinant nucleotide molecules encoding same, recombinant Listeria strains comprising same, and immunogenic and therapeutic methods utilizing same.
- Who is the assignee on this patent?
- Advaxis Inc, Univ Pennsylvania
- What technology area does this patent fall under?
- Primary CPC classification C12N9/6445. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Sep 20 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).